Experimental oral therapy PrimeC shows safety and signals of clinical benefit in ALS

AI Summary

A phase 2b clinical trial of PrimeC, an experimental oral therapy for ALS, found the drug to be safe and well-tolerated, with exploratory signals suggesting potential clinical benefit. The PARADIGM study, conducted by Mass General Brigham and Barrow Neurological Institute, was published in JAMA Neurology.

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement and potential clinical benefits. Results of the PARADIGM study, led by researchers at Mass General Brigham Neuroscience Institute and Barrow Neurological Institute, were published in JAMA Neurology.